Advertisement
"Safety has always been and continues to be our top priority," said LindaA. Suydam, D.P.A, president of CHPA. "Last fall, the leading makers of OTC,oral cough and cold medicines for infants voluntarily withdrew these medicinesout of concern that their potential misuse could lead to possible overdoseamong very young children. While CHPA and its member companies believe thatthe large majority of parents and caregivers know how to safely andappropriately administer these medicines, and that they are safe when taken asdirected, we took this voluntary action recognizing that infants areespecially vulnerable to accidental misuse."
Advertisement
"Today's decision by FDA reaffirms the correct course of action taken bythe leading makers of these medicines last fall," Suydam added. "Since then,we have been working with the retail community, healthcare professionals andFDA officials to ensure that parents have the tools they need to safely andappropriately administer OTC oral cough and cold medicines to children overthe age of two. We have already begun a new educational campaign for parentsand caregivers of small children, and remain intent on ensuring that parentshave access to the very best OTCs for their families, as well as accurateinformation about safe and appropriate OTC cough and cold medicine use inchildren."
Helpful tips for parents and caregivers can be found athttp://www.OTCsafety.org/Parents.
CHPA is the 127-year-old-trade association representing U.S. manufacturersand distributors of over-the-counter medicines and nutritional supplementproducts.www.chpa-info.org
SOURCE Consumer Healthcare Products Association
